{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:13:29Z","timestamp":1791515609254,"version":"4.3.4"},"reference-count":136,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seminarsinnephrology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nephrology"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.semnephrol.2018.08.005","type":"journal-article","created":{"date-parts":[[2018,11,6]],"date-time":"2018-11-06T11:51:06Z","timestamp":1541505066000},"page":"600-617","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"title":["Heart Failure in End-Stage Kidney Disease: Pathophysiology, Diagnosis, and Therapeutic Strategies"],"prefix":"10.1016","volume":"38","author":[{"given":"Janani","family":"Rangaswami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"McCullough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semnephrol.2018.08.005_bib0001","series-title":"epidemiology of kidney disease in the United States","year":"2017"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0002","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/ki.1995.132","article-title":"Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors","volume":"47","author":"Harnett","year":"1995","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0003","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0272-6386(03)00359-7","article-title":"Heart failure as a cause for hospitalization in chronic dialysis patients","volume":"41","author":"Trespalacios","year":"2003","journal-title":"Am J Kidney Dis"},{"issue":"Suppl 1","key":"10.1016\/j.semnephrol.2018.08.005_bib0004","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/ndt\/17.suppl_1.29","article-title":"Left ventricular alterations and end-stage renal disease","volume":"17","author":"London","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0005","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.jcmg.2013.09.025","article-title":"Defining the natural history of uremic cardiomyopathy in chronic kidney disease: the role of cardiovascular magnetic resonance","volume":"7","author":"Edwards","year":"2014","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0006","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.jacc.2015.11.065","article-title":"Influence of chronic renal failure on cardiac structure","volume":"67","author":"McCullough","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0007","doi-asserted-by":"crossref","first-page":"805","DOI":"10.2215\/CJN.07761109","article-title":"Left ventricular hypertrophy in new hemodialysis patients without symptomatic cardiac disease","volume":"5","author":"Foley","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0008","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1053\/j.ajkd.2012.09.008","article-title":"Effect of early initiation of dialysis on cardiac structure and function: results from the echo substudy of the IDEAL trial","volume":"61","author":"Whalley","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0009","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2215\/CJN.06020612","article-title":"A longitudinal study of left ventricular function and structure from CKD to ESRD: the CRIC study","volume":"8","author":"Bansal","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0010","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1523-1755.2005.00086.x","article-title":"Clinical and pathologic characteristics of dilated cardiomyopathy in hemodialysis patients","volume":"67","author":"Aoki","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0011","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/j.lfs.2013.05.008","article-title":"Indoxyl sulfate promotes cardiac fibrosis with enhanced oxidative stress in hypertensive rats","volume":"92","author":"Yisireyili","year":"2013","journal-title":"Life Sci"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0012","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/ki.1992.390","article-title":"Reduced capillary density in the myocardium of uremic rats\u2013a stereological study","volume":"42","author":"Amann","year":"1992","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0013","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jcmg.2013.11.010","article-title":"Molecular and cellular correlates of cardiac function in end-stage DCM: a study using speckle tracking echocardiography","volume":"7","author":"Cordero-Reyes","year":"2014","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0014","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.amjhyper.2004.07.017","article-title":"Association between hypervolemia and ventricular hypertrophy in hemodialysis patients","volume":"17","author":"Martin","year":"2004","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0015","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1093\/eurheartj\/ehx114","article-title":"Dialysis fistulas and heart failure","volume":"38","author":"McCullough","year":"2017","journal-title":"Eur Heart J"},{"issue":"Suppl 1","key":"10.1016\/j.semnephrol.2018.08.005_bib0016","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.2215\/CJN.04860709","article-title":"Left ventricular mass in chronic kidney disease and ESRD","volume":"4","author":"Glassock","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0017","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000100106","article-title":"Role of aldosterone in left ventricular hypertrophy among African-American patients with end-stage renal disease on hemodialysis","volume":"27","author":"Steigerwalt","year":"2007","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0018","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1056\/NEJMoa1001593","article-title":"In-center hemodialysis six times per week versus three times per week","volume":"363","author":"Chertow","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0019","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1081\/JDI-100001291","article-title":"Parathormon, calcium, phosphorus, and left ventricular structure and function in normotensive hemodialysis patients","volume":"23","author":"Strozecki","year":"2001","journal-title":"Ren Fail"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0020","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1001\/jama.2012.120","article-title":"Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial","volume":"307","author":"Thadhani","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0021","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/ndt\/gfr447","article-title":"Parathyroid hormone and phosphorus overload in uremia: impact on cardiovascular system","volume":"27","author":"Custodio","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0022","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/eurjhf\/hfq134","article-title":"Plasma parathyroid hormone and risk of congestive heart failure in the community","volume":"12","author":"Hagstrom","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0023","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/j.1525-139X.2008.00454.x","article-title":"Hypertrophy and fibrosis in the cardiomyopathy of uremia\u2013beyond coronary heart disease","volume":"21","author":"Gross","year":"2008","journal-title":"Semin Dial"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0024","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1053\/j.ajkd.2008.04.018","article-title":"Effect of sirolimus on left ventricular hypertrophy in kidney transplant recipients: a 1-year nonrandomized controlled trial","volume":"52","author":"Paoletti","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0025","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1097\/TP.0000000000001739","article-title":"Cardiovascular parameters to 2 years after kidney transplantation following early switch to everolimus without calcineurin inhibitor therapy: an analysis of the randomized ELEVATE study","volume":"101","author":"Holdaas","year":"2017","journal-title":"Transplantation"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0026","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1172\/JCI46122","article-title":"FGF23 induces left ventricular hypertrophy","volume":"121","author":"Faul","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0027","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1007\/s10554-014-0480-2","article-title":"Impact of hemodialysis, left ventricular mass and FGF-23 on myocardial mechanics in end-stage renal disease: a three-dimensional speckle tracking study","volume":"30","author":"Kovacs","year":"2014","journal-title":"Int J Cardiovasc Imaging"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0028","doi-asserted-by":"crossref","first-page":"951","DOI":"10.3109\/0886022X.2015.1052945","article-title":"Correlation between hypervolemia, left ventricular hypertrophy and fibroblast growth factor 23 in hemodialysis patients","volume":"37","author":"Unver","year":"2015","journal-title":"Ren Fail"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0029","doi-asserted-by":"crossref","first-page":"565","DOI":"10.2459\/JCM.0b013e3283536859","article-title":"Fibroblast growth factor-23 and interleukin-6 are risk factors for left ventricular hypertrophy in peritoneal dialysis patients","volume":"13","author":"Liu","year":"2012","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0030","doi-asserted-by":"crossref","first-page":"e79302","DOI":"10.1371\/journal.pone.0079302","article-title":"B-type natriuretic peptide and prognosis of end-stage renal disease: a meta-analysis","volume":"8","author":"Cheng","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0031","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1681\/ASN.V115912","article-title":"Serial change in echocardiographic parameters and cardiac failure in end-stage renal disease","volume":"11","author":"Foley","year":"2000","journal-title":"J Am Soc Nephrol"},{"issue":"Suppl 3","key":"10.1016\/j.semnephrol.2018.08.005_bib0032","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients","volume":"45","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0033","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/S0735-1097(99)00118-7","article-title":"Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort","volume":"33","author":"Vasan","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0034","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1159\/000187476","article-title":"The reliability and validity of echocardiographic measurement of left ventricular mass index in hemodialysis patients","volume":"65","author":"Harnett","year":"1993","journal-title":"Nephron"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0035","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1681\/ASN.V12122768","article-title":"Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis","volume":"12","author":"Zoccali","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0036","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1093\/eurheartj\/ehm037","article-title":"How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology","volume":"28","author":"Paulus","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0037","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2005.08.022","volume":"46","author":"Hunt","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0038","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0039","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.jacc.2014.01.020","article-title":"Proposal for a functional classification system of heart failure in patients with end-stage renal disease: proceedings of the acute dialysis quality initiative (ADQI) XI workgroup","volume":"63","author":"Chawla","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0040","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.jacc.2015.12.052","article-title":"Echocardiography criteria for structural heart disease in patients with end-stage renal disease initiating hemodialysis","volume":"67","author":"Hickson","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0041","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s10554-016-1059-x","article-title":"Subclinical markers of cardiovascular disease predict adverse outcomes in chronic kidney disease patients with normal left ventricular ejection fraction","volume":"33","author":"Sulemane","year":"2017","journal-title":"Int J Cardiovasc Imaging"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0042","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1111\/echo.13284","article-title":"Left atrial and ventricular systolic and diastolic myocardial mechanics in patients with end-stage renal disease","volume":"33","author":"Calleja","year":"2016","journal-title":"Echocardiography"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0043","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/j.amjcard.2015.08.028","article-title":"Echocardiographic strain and mortality in black Americans with end-stage renal disease on hemodialysis","volume":"116","author":"Pressman","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0044","doi-asserted-by":"crossref","first-page":"4422","DOI":"10.1093\/ndt\/gfs090","article-title":"Multidirectional myocardial systolic function in hemodialysis patients with preserved left ventricular ejection fraction and different left ventricular geometry","volume":"27","author":"Wang","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0045","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.kint.2016.06.014","article-title":"Defining myocardial tissue abnormalities in end-stage renal failure with cardiac magnetic resonance imaging using native T1 mapping","volume":"90","author":"Rutherford","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0046","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.kint.2016.07.014","article-title":"Novel cardiac nuclear magnetic resonance method for noninvasive assessment of myocardial fibrosis in hemodialysis patients","volume":"90","author":"Graham-Brown","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0047","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1093\/ndt\/gfp395","article-title":"NT-proBNP, fluid volume overload and dialysis modality are independent predictors of mortality in ESRD patients","volume":"25","author":"Paniagua","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0048","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1053\/j.ajkd.2007.08.017","article-title":"Relationships of N-terminal pro-B-natriuretic peptide and cardiac troponin T to left ventricular mass and function and mortality in asymptomatic hemodialysis patients","volume":"50","author":"Satyan","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0049","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1161\/01.HYP.0000170140.36633.8f","article-title":"Effect of compensated renal dysfunction on approved heart failure markers: direct comparison of brain natriuretic peptide (BNP) and N-terminal pro-BNP","volume":"46","author":"Luchner","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0050","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1681\/ASN.V1271508","article-title":"Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients","volume":"12","author":"Zoccali","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0051","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/1454986","article-title":"Natriuretic peptides as biomarkers for congestive states: the cardiorenal divergence","volume":"2017","author":"Koratala","year":"2017","journal-title":"Dis Markers"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0052","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1042\/cs0820127","article-title":"Effect of haemodialysis on plasma levels of brain natriuretic peptide in patients with chronic renal failure","volume":"82","author":"Lang","year":"1992","journal-title":"Clin Science (Lond)"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0053","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1055\/s-2007-1001675","article-title":"Changes in brain natriuretic peptide and atrial natriuretic peptide plasma concentrations during hemodialysis in patients with chronic renal failure","volume":"26","author":"Haug","year":"1994","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0054","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1053\/j.ackd.2004.11.002","article-title":"Changes in B-type natriuretic peptide levels in hemodialysis and the effect of depressed left ventricular function","volume":"12","author":"Safley","year":"2005","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0055","first-page":"457","article-title":"Significance of brain natriuretic peptides in patients on continuous ambulatory peritoneal dialysis","volume":"10","author":"Nakatani","year":"2002","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0056","article-title":"FDA clears new intended uses for Roche Diagnostics troponin T test","year":"2004","journal-title":"Trade News"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0057","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1053\/j.ajkd.2017.10.016","article-title":"Prognostic value of high-sensitivity versus conventional cardiac troponin T assays among patients with type 2 diabetes mellitus undergoing maintenance hemodialysis","volume":"71","author":"Keller","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0058","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1053\/j.ajkd.2012.11.034","article-title":"Association of cardiac troponin T with left ventricular structure and function in CKD","volume":"61","author":"Mishra","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0059","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1373\/clinchem.2015.251835","article-title":"Prognostic value of serial changes in high-sensitivity cardiac troponin I and T over 3 months using reference change values in hemodialysis patients","volume":"62","author":"Sandoval","year":"2016","journal-title":"Clin Chem"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0060","doi-asserted-by":"crossref","first-page":"914","DOI":"10.2215\/CJN.03900808","article-title":"Hemodialysis-induced cardiac injury: determinants and associated outcomes","volume":"4","author":"Burton","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0061","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1159\/000376603","article-title":"Cardiac troponin T and hydration status as prognostic markers in hemodialysis patients","volume":"40","author":"Hoppe","year":"2015","journal-title":"Blood Purif"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0062","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1053\/ajkd.2002.33914","article-title":"Troponin is related to left ventricular mass and predicts all-cause and cardiovascular mortality in hemodialysis patients","volume":"40","author":"Mallamaci","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0063","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00392-010-0125-y","article-title":"Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study","volume":"99","author":"Lok","year":"2010","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0064","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3909\/ricm0624","article-title":"Galectin-3: a novel blood test for the evaluation and management of patients with heart failure","volume":"12","author":"McCullough","year":"2011","journal-title":"Rev Cardiovasc Med"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0065","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ahj.2016.05.018","article-title":"Independent and incremental prognostic value of novel cardiac biomarkers in chronic hemodialysis patients","volume":"179","author":"Obokata","year":"2016","journal-title":"Am Heart J"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0066","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1681\/ASN.2014010093","article-title":"Galectin-3, renal function, and clinical outcomes: results from the LURIC and 4D studies","volume":"26","author":"Drechsler","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0067","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/CIRCHEARTFAILURE.113.000457","article-title":"Soluble concentrations of the interleukin receptor family member ST2 and beta-blocker therapy in chronic heart failure","volume":"6","author":"Gaggin","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0068","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1097\/01.ASN.0000135053.98172.D6","article-title":"Inflammation, residual kidney function, and cardiac hypertrophy are interrelated and combine adversely to enhance mortality and cardiovascular death risk of peritoneal dialysis patients","volume":"15","author":"Wang","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0069","doi-asserted-by":"crossref","first-page":"366","DOI":"10.5414\/CN107169","article-title":"Echocardiographic changes following hemodialysis initiation in patients with advanced chronic kidney disease and symptomatic heart failure with reduced ejection fraction","volume":"77","author":"Ganda","year":"2012","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0070","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1681\/ASN.V12122759","article-title":"Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study","volume":"12","author":"London","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0071","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1681\/ASN.2005040392","article-title":"Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: a prospective, controlled study","volume":"16","author":"Ayus","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0072","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1001\/jama.298.11.1291","article-title":"Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial","volume":"298","author":"Culleton","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0073","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1093\/ndt\/17.8.1518","article-title":"Improvement in ejection fraction by nocturnal haemodialysis in end-stage renal failure patients with coexisting heart failure","volume":"17","author":"Chan","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0074","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1038\/ki.2011.213","article-title":"The effects of frequent nocturnal home hemodialysis: the Frequent Hemodialysis Network Nocturnal Trial","volume":"80","author":"Rocco","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0075","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1159\/000441966","article-title":"The effect of increased frequency of hemodialysis on volume-related outcomes: a secondary analysis of the Frequent Hemodialysis Network Trials","volume":"41","author":"Raimann","year":"2016","journal-title":"Blood Purif"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0076","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1053\/j.ajkd.2016.05.025","article-title":"Intensive hemodialysis, left ventricular hypertrophy, and cardiovascular disease","volume":"68","author":"McCullough","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0077","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1159\/000481248","article-title":"Cardiac remodelling in patients undergoing in-centre nocturnal haemodialysis: results from the MIDNIGHT study, a non-randomized controlled trial","volume":"44","author":"Graham-Brown","year":"2017","journal-title":"Blood Purif"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0078","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.2215\/CJN.04470709","article-title":"Hemodialysis-induced repetitive myocardial injury results in global and segmental reduction in systolic cardiac function","volume":"4","author":"Burton","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0079","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1681\/ASN.2014020222","article-title":"Association of mortality risk with various definitions of intradialytic hypotension","volume":"26","author":"Flythe","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0080","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.2215\/CJN.02680314","article-title":"Intradialytic hypotension and risk of cardiovascular disease","volume":"9","author":"Stefansson","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0081","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1053\/j.ajkd.2016.05.021","article-title":"Intensive hemodialysis and treatment complications and tolerability","volume":"68","author":"Morfin","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0082","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.2215\/CJN.05200610","article-title":"Frequent hemodialysis schedules are associated with reduced levels of dialysis-induced cardiac injury (myocardial stunning)","volume":"6","author":"Jefferies","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0083","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.2215\/CJN.02010606","article-title":"Dialysis-induced regional left ventricular dysfunction is ameliorated by cooling the dialysate","volume":"1","author":"Selby","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0084","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1053\/j.ajkd.2006.01.012","article-title":"Occurrence of regional left ventricular dysfunction in patients undergoing standard and biofeedback dialysis","volume":"47","author":"Selby","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0085","doi-asserted-by":"crossref","first-page":"e427","DOI":"10.1097\/MD.0000000000000427","article-title":"Changes in echocardiographic parameters according to the rate of residual renal function decline in incident peritoneal dialysis patients","volume":"94","author":"Koo","year":"2015","journal-title":"Medicine"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0086","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1046\/j.1523-1755.2003.00887.x","article-title":"Effect of icodextrin on volume status, blood pressure and echocardiographic parameters: a randomized study","volume":"63","author":"Konings","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0087","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1046\/j.1523-1755.2003.00165.x","article-title":"Impact of dialysis modality on survival of new ESRD patients with congestive heart failure in the United States","volume":"64","author":"Stack","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0088","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/ki.2011.233","article-title":"Survival advantage of hemodialysis relative to peritoneal dialysis in patients with end-stage renal disease and congestive heart failure","volume":"80","author":"Sens","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0089","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1111\/j.1523-1755.2004.66028.x","article-title":"The differential impact of risk factors on mortality in hemodialysis and peritoneal dialysis","volume":"66","author":"Vonesh","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0090","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1053\/j.ajkd.2007.04.020","article-title":"Relationship between interdialytic weight gain and blood pressure among prevalent hemodialysis patients","volume":"50","author":"Inrig","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0091","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1161\/HYPERTENSIONAHA.108.125674","article-title":"Dry-weight reduction in hypertensive hemodialysis patients (DRIP): a randomized, controlled trial","volume":"53","author":"Agarwal","year":"2009","journal-title":"Hypertension"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0092","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2215\/CJN.00880207","article-title":"Relative blood volume changes underestimate total blood volume changes during hemodialysis","volume":"2","author":"Dasselaar","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0093","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1053\/ajkd.2002.36894","article-title":"The role of blood volume reduction in the genesis of intradialytic hypotension","volume":"40","author":"Andrulli","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0094","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1046\/j.1523-1755.2002.00523.x","article-title":"Blood volume monitoring in intermittent hemodialysis for acute renal failure","volume":"62","author":"Tonelli","year":"2002","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.semnephrol.2018.08.005_bib0095","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/ndt\/gfp487","article-title":"Guided optimization of fluid status in haemodialysis patients","volume":"25","author":"Machek","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0096","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s11255-016-1471-0","article-title":"Dry weight assessment by combined ultrasound and bioimpedance monitoring in low cardiovascular risk hemodialysis patients: a randomized controlled trial","volume":"49","author":"Siriopol","year":"2017","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0097","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1093\/ndt\/gft260","article-title":"Predicting mortality in haemodialysis patients: a comparison between lung ultrasonography, bioimpedance data and echocardiography parameters","volume":"28","author":"Siriopol","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0098","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.2215\/CJN.11111012","article-title":"Asymptomatic pulmonary congestion and physical functioning in hemodialysis patients","volume":"8","author":"Enia","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0099","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1093\/ndt\/gfg298","article-title":"Inferior vena cava diameter determines left ventricular geometry in continuous ambulatory peritoneal dialysis patients: an echocardiographic study","volume":"18","author":"Toprak","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0100","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.2215\/CJN.09321010","article-title":"Inferior vena cava diameter and left atrial diameter measure volume but not dry weight","volume":"6","author":"Agarwal","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0101","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/s12882-017-0639-x","article-title":"Blood volume-monitored regulation of ultrafiltration to decrease the dry weight in fluid-overloaded hemodialysis patients: a randomized controlled trial","volume":"18","author":"Antlanger","year":"2017","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0102","doi-asserted-by":"crossref","first-page":"F793","DOI":"10.1152\/ajprenal.00096.2005","article-title":"Internal sodium balance in DOCA-salt rats: a body composition study","volume":"289","author":"Titze","year":"2005","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0103","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/ki.2014.269","article-title":"Magnetic resonance-determined sodium removal from tissue stores in hemodialysis patients","volume":"87","author":"Dahlmann","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0104","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1053\/j.ajkd.2011.10.047","article-title":"Utilization and costs of cardiovascular disease medications in dialysis patients in Medicare Part D","volume":"59","author":"Frankenfield","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0105","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1093\/ndt\/gfr460","article-title":"Beta-blockers and cardiovascular outcomes in dialysis patients: a cohort study in Ontario, Canada","volume":"27","author":"Kitchlu","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0106","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/S0735-1097(03)00241-9","article-title":"Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial","volume":"41","author":"Cice","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0107","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1053\/j.ajkd.2015.10.029","article-title":"The beta-Blocker to Lower Cardiovascular Dialysis Events (BLOCADE) feasibility study: a randomized controlled trial","volume":"67","author":"Roberts","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0108","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/j.1552-4604.1985.tb02864.x","article-title":"Pharmacokinetics of atenolol in patients treated with chronic hemodialysis or peritoneal dialysis","volume":"25","author":"Campese","year":"1985","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0109","first-page":"607","article-title":"Pharmacokinetics of antihypertensive drugs (atenolol, metoprolol, propranolol and clonidine) and their metabolites during intermittent haemodialysis in humans","volume":"15","author":"Niedermayer","year":"1978","journal-title":"Proc Eur Dial Transplant Assoc"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0110","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1681\/ASN.2014040324","article-title":"beta-Blocker dialyzability and mortality in older patients receiving hemodialysis","volume":"26","author":"Weir","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0111","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3317\/jraas.2002.040","article-title":"Mortality benefit of angiotensin-converting enzyme inhibitors after cardiac events in patients with end-stage renal disease","volume":"3","author":"McCullough","year":"2002","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0112","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ahj.2011.05.004","article-title":"Angiotensin-converting enzyme inhibitors and cardiovascular outcomes in patients on maintenance hemodialysis","volume":"162","author":"Chang","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0113","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/sj.ki.5001657","article-title":"Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies","volume":"70","author":"Zannad","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0114","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.jacc.2010.03.105","article-title":"Effects of telmisartan added to angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial","volume":"56","author":"Cice","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0115","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1159\/000438821","article-title":"Angiotensin converting enzyme inhibitor dialyzability and outcomes in older patients receiving hemodialysis","volume":"40","author":"Weir","year":"2015","journal-title":"Blood Purif"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0116","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/clc.20838","article-title":"Spironolactone use in heart failure patients with end-stage renal disease on hemodialysis: is it safe","volume":"33","author":"Chua","year":"2010","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0117","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.jacc.2013.09.056","article-title":"Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients","volume":"63","author":"Matsumoto","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0118","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/ki.1980.93","article-title":"Mechanism and prevention of cardiac arrhythmias in chronic hemodialysis patients","volume":"17","author":"Morrison","year":"1980","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0119","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/cpt1977215536","article-title":"Studies on digitalis. XI. Digitoxin metabolism in patients with impaired renal function","volume":"21","author":"Storstein","year":"1977","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0120","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1681\/ASN.2009101047","article-title":"Digoxin associates with mortality in ESRD","volume":"21","author":"Chan","year":"2010","journal-title":"J Am Soc Nephrol"},{"issue":"Suppl 1","key":"10.1016\/j.semnephrol.2018.08.005_bib0121","first-page":"Svii","article-title":"US Renal Data System 2014 annual data report: epidemiology of kidney disease in the United States","volume":"66","author":"Saran","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0122","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1159\/000074934","article-title":"Chronic kidney disease and sudden death: strategies for prevention","volume":"22","author":"McCullough","year":"2004","journal-title":"Blood Purif"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0123","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1053\/j.ajkd.2013.12.009","article-title":"Implantable cardioverter-defibrillators for primary prevention of sudden cardiac death in CKD: a meta-analysis of patient-level data from 3 randomized trials","volume":"64","author":"Pun","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0124","doi-asserted-by":"crossref","first-page":"e99418","DOI":"10.1371\/journal.pone.0099418","article-title":"A meta-analysis of mortality in end-stage renal disease patients receiving implantable cardioverter defibrillators (ICDs)","volume":"9","author":"Chen","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0125","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.joa.2017.05.002","article-title":"Long-term survival of implantable cardioverter defibrillator recipients with end-stage renal disease","volume":"33","author":"El-Chami","year":"2017","journal-title":"J Arrhythm"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0126","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/hdi.12577","article-title":"Subcutaneous defibrillators for dialysis patients","volume":"22","author":"Vachharajani","year":"2018","journal-title":"Hemodial Int"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0127","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1053\/j.ajkd.2015.01.028","article-title":"Subcutaneous implantable cardioverter defibrillator for dialysis patients: a strategy to reduce central vein stenoses and infections","volume":"66","author":"Dhamija","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0128","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s10840-015-0093-2","article-title":"Outcomes of subcutaneous implantable cardioverter-defibrillator implantation in patients on hemodialysis","volume":"45","author":"Koman","year":"2016","journal-title":"J Interv Cardiac Electrophysiol"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0129","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1111\/jce.12705","article-title":"Outcome of subcutaneous implantable cardioverter defibrillator implantation in patients with end-stage renal disease on dialysis","volume":"26","author":"El-Chami","year":"2015","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"Suppl 1","key":"10.1016\/j.semnephrol.2018.08.005_bib0130","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.2215\/CJN.05980809","article-title":"The state of chronic kidney disease, ESRD, and morbidity and mortality in the first year of dialysis","volume":"4","author":"Collins","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0131","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1093\/ndt\/gfv295","article-title":"Trends in dialysis modality choice and related patient survival in the ERA-EDTA Registry over a 20-year period","volume":"31","author":"van de Luijtgaarden","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0132","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1093\/eurheartj\/ehx045","article-title":"Long-term cardiovascular changes following creation of arteriovenous fistula in patients with end stage renal disease","volume":"38","author":"Reddy","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0133","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.healun.2009.11.604","article-title":"Ideal methodology to assess systemic blood pressure in patients with continuous-flow left ventricular assist devices","volume":"29","author":"Bennett","year":"2010","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0134","doi-asserted-by":"crossref","first-page":"484","DOI":"10.2215\/CJN.06210612","article-title":"Renal failure in patients with left ventricular assist devices","volume":"8","author":"Patel","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0135","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/MAT.0000000000000020","article-title":"Peritoneal dialysis after left ventricular assist device placement","volume":"60","author":"Guglielmi","year":"2014","journal-title":"ASAIO J"},{"key":"10.1016\/j.semnephrol.2018.08.005_bib0136","doi-asserted-by":"crossref","unstructured":"Edwards NC, Hayer MK, Ferro CJ, Townend JN, Steeds RP. CKD associated cardiomyopathy: molecular mechanisms, imaging modalities, disease evolution and interventions. Textbook of cardio-nephrology: confluence of the heart and kidney in clinical practice. Cham Switzerland: Springer International; 2017.","DOI":"10.1007\/978-3-319-56042-7_5"}],"container-title":["Seminars in Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929518301372?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929518301372?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T23:32:14Z","timestamp":1759447934000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0270929518301372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":136,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S0270929518301372"],"URL":"https:\/\/doi.org\/10.1016\/j.semnephrol.2018.08.005","relation":{},"ISSN":["0270-9295"],"issn-type":[{"value":"0270-9295","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Heart Failure in End-Stage Kidney Disease: Pathophysiology, Diagnosis, and Therapeutic Strategies","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nephrology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semnephrol.2018.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}